



Quest
LABORATORIES LIMITED

(Formerly known as Quest Laboratories Pvt. Ltd.)

CIN No.: U24232MP1998PLC012850

To,
National Stock Exchange of India Ltd.
Exchange Plaza, C-1, Block G,
BandraKurla Complex,
Bandra (E)
Mumbai – 400 051

NSE Symbol: QUESTLAB; ISIN - INE0TNW01017

Dear Sir/ Madam,

Subject: Investors Update for Half Year and Financial Year ended 31st March, 2024.

Reference :-Disclosure under Regulation 30 read with schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015

With Reference to the captioned subject, we attach herewith the Investor Update for the Half Year and Financial Year ended 31st March, 2024.

You are requested to take the above on your record.

Thanking you,

Yours faithfully,

For, QUEST LABORATORIES LIMITED

ANIL KUMAR SABARWAL
MANAGING DIRECTOR
DIN: 00646133

Regd. Off. & Plant : Plot No. 45, Opp. Kissan Pipe Unit 4, Sector III, Pithampur Dist. Dhar (MP) 454775.



cmd@questlabltd.com
sales@questlabltd.com
investor@questlabltd.com



www.questlabltd.com
GST No.: 23AAACQ1040R1ZH



+91 9329095934
+91 7999149001
(F) +91 07292292374



Quest Laboratories Limited (NSE SYMBOL: QUESTLAB), is engaged in manufacturing of Drugs & Medicine, has announced its Audited Financial Results for the Half Year and Financial Year ended 31st March, 2024.

Standalone Key Financial Highlights:

FY 24

Particulars (in Lacs)	FY 24	FY 23	YoY Change
Total Income	8279.19	6186.60	↑ 33.82%
EBITDA	1577.76	806.98	↑ 95.51%
PAT	1009.39	504.49	↑ 100.08%
EPS (Rs.)*	9.11	46.76	↓ 80.52%

- EBITDA Margin of 19.05%
- PAT Margin of 12.19%

(* The Decrease in Earning Per Share (EPS) is due to Increase in number of shares from 1078760 to 101937600 & Paid up Equity Share Capital of the Company from Rs. 1,07,87,600 to Rs. 11,93,76,000.)

Mr. Anil Kumar Sabarwal, Chairman & Managing Director of Quest Laboratories Limited, proudly highlighted the company's remarkable performance: “We are thrilled with our outstanding financial performance in FY24, highlighted by a 100% surge in net profit (PAT) and a 34% increase in total income. Our expansion into business for the FY25 as follows:-

- Export to African Countries.
- New Drugs Launch.
- Exploring the Domestic Market full fledge.
- Introduction of range of New Molecules.

This shall paves the way for significant growth in Sales & Profits.”

Disclaimer

This document contains forward-looking statements, which are not historical facts and are subject to risks and uncertainties such as government actions, local developments, and technological risks. The Company is not responsible for any actions taken based on these statements and does not commit to publicly updating them to reflect future events or circumstances.

For Further Information Please Contact



QUEST LABORATORIES LIMITED

Jayesh Jain

Company Secretary & Compliance Officer

+91 9301654045

cs@questlabltd.com

07292-292374

www.questlabltd.com